Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029723 | 0.89 | GRM2 (0.56) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL2024263 | 0.88 | GRM2 (0.54) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL2018587 | 0.88 | GRM2 (0.47) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL13613663 | 0.88 | GRM2 (0.56) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL12441933 | 0.88 | GRM2 (0.56) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL2022984 | 0.87 | GRM2 (0.47) | GRM2HCRTR1HCRTR2 | |
| SCHEMBL2025757 | 0.87 | GRM2 (0.55) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL1003383 | 0.87 | GRM2 (0.47) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL2029663 | 0.87 | GRM2 (0.55) | GRM2ALDH1A1GRIN2BCHRM5TSHR | |
| SCHEMBL2027520 | 0.86 | PARK7 (0.46) | GRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521722-B1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2015-05-06 | — | — | EP | claimed |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2521722-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | AstraZeneca AB (SE) | 2012-11-14 | — | — | EP | claimed |
| WO-2011084098-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2011-07-14 | — | — | WO | claimed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | claimed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | claimed |
| EP-2521722-B1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2015-05-06 | — | — | EP | disclosed |
| EP-2521722-B1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2015-05-06 | — | — | EP | disclosed |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2521722-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | AstraZeneca AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | GRM4, GRIK4, GRIA4 | GRM2 6/4885ALDH1A1 3129/4885GRIN2B 23/4885 |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | GRM2 3/4885ALDH1A1 1757/4885GRIN2B 11/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885ALDH1A1 1582/4885GRIN2B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.